The DOI matches its Crossref record.
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Abstract
PURPOSE: This trial investigated the toxicity and efficacy of docetaxel as first-line chemotherapy in women with heavily pretreated advanced breast cancer. PATIENTS AND METHODS: From April 1992 to August 1992, 35 patients with advanced breast cancer from 29 to 65 years of age with a performance status of 0 to 2 were entered onto the study. Docetaxel 100 mg/m2 was administered every 3 weeks as a 1-hour infusion on day 1 without routine premedication for hypersensitivity reactions. Thirty-one patients were assessable for response. Previous adjuvant chemotherapy had been given to 11 patients. RESULTS: Five complete responses (CRs) and 16 partial responses (PRs) were observed, for an overall response rate of 67.7% (95% confidence interval, 49% to 83%). A CR occurred at 13 of 45 assessable sites (four liver, two lung, three breast, three lymph node, and one skin). The median duration of response was 44+ weeks, the median time to disease progression 37+ weeks, and the median overall survival time 16+ months. Among 34 patients assessable for toxicity (177 cycles; median, five cycles per patient), the following side effects were reported: nadir neutropenia grade 3 (three patients); grade 4 (31 patients); no grade 3 to 4 infection, acute hypersensitivity-like reaction (10 patients); grade 2 to 3 alopecia (all patients); and grade 2 to 3 nausea and vomiting (six patients). Fluid retention occurred in 26 patients and consisted of weight gain, edema alone (15 patients), or edema associated with serous effusion (11 patients). This side effect led to treatment discontinuation in 16 of 21 responding patients after a median of five cycles and a median cumulative dose of docetaxel of 574 mg/m2. CONCLUSION: Our data suggest that docetaxel has major antitumor activity when used as a single cytotoxic agent as first-line chemotherapy in advanced breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
Groopman, J. E., & Itri, L. M. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.19.1616 · Cited by 929
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
Rowinsky, M. (1997) · Annual Review of Medicine · doi:10.1146/annurev.med.48.1.353 · Cited by 721
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
Hesketh, P. J., Kris, M. G., Grunberg, S. M., Beck, T., Hainsworth, J. D., Harker, G., Aapro, M. S., Gandara, D., & Lindley, C. M. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.103 · Cited by 605
Roché, H., Fumoleau, P., Spielmann, M., Canon, J.-L., Delozier, T., Serin, D., Symann, M., Kerbrat, P., Soulié, P., Eichler, F., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3916 · Cited by 577
Self-citation
Metadata
- Authors
- Chevallier, B., Fumoleau, P., Kerbrat, P., Dieras, V, Roche, H., Krakowski, I., Azli, N., Bayssas, M., Lentz, M. A., & Van Glabbeke, M.
- Venue
- Journal of Clinical Oncology
- Published
- 1995-02
- Volume
- 13
- Issue
- 2
- Pages
- 314-322
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1940165440
- Cited by
- 222
- References
- 0
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. https://app.cochat.ai/papers/10.1200/jco.1995.13.2.314
- The paper
- Chevallier, B., Fumoleau, P., Kerbrat, P., Dieras, V, Roche, H., Krakowski, I., Azli, N., Bayssas, M., Lentz, M. A., & Van Glabbeke, M. (1995). Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1995.13.2.314
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.